Navigation Links
Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade
Date:11/2/2011

ENGLEWOOD, Colo., Nov. 2, 2011 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, has released a software upgrade for its ExactaMix® Automated Compounding Devices (ACD).  The new functionality includes 14 updates that provide Directors of Pharmacy with enhanced patient safety measures and features.

Hospital pharmacies worldwide use ExactaMix 2400 (EM2400) and ExactaMix 1200 (EM1200) to compound large- and small-volume parenteral doses.  Baxa Corporation leads the ACD category with 65% of the global US market share, according to a recent poll in Pharmacy Purchasing & Products magazine.

Improved Efficiency, Added Safety Set Industry Standard

ExactaMix ACDs automatically compound multi-ingredient sterile doses, minimizing the risk of measurement errors, wrong drug selection, touch contamination and patient infection in the preparation of solutions for total parenteral nutrition (TPN), cardioplegia, dialysis and epidural delivery.  

To facilitate the upgrade, current ExactaMix customers will have one-on-one live installation support.  The ExactaMix software release includes the following key features for EM2400 and EM1200 users:

  • Water is now the default calibration ingredient for the US market.  The calibration source was redefined to allow multiple water calibration products.
  • The current patient formula is unloaded when the user exits the compounder screen, reducing the potential for the user to pump a wrong formula into the bag.
  • New priming process improves the purging of air bubbles in the inlets prior to pumping, enhancing the user prime process.
  • Integration with DoseEdge® Pharmacy Workflow Manager enables pharmacies to export MixCheck™ Report data for use with DoseEdge TPN.

State-of-the-art Baxa compounding technology delivers final bag accuracies within + 3% with barcode ingredient verification, and pumps a typical three-liter nutrition bag in approximately 3.5 minutes – nearly two times faster than the industry average.  ExactaMix provides volumetric delivery and gravimetric check with the ability to mix both micro and macro ingredients as low as 0.2 mL.  ExactaMix compounding efficiency enables pharmacy professionals to focus on patient care with the confidence that safety, regulatory compliance and preparation accuracy goals are met.

"The first company to offer automated compounding of both micro and macro ingredients in a single device, Baxa ACDs now serve over 20,000 patients daily across the globe," said Mark Miller, Product Manager at Baxa Corporation.  "In fact, 2012 marks the 10-year anniversary of doses compounded safely on the ExactaMix 2400 Compounder."

Baxa Corporation reliably and consistently enables pharmacists in more than 3,000 hospitals worldwide to safely prepare and administer intravenous therapies.  To learn more about the ExactaMix line of ACDs, visit www.baxa.com/exactamix/.  

For additional information on Baxa IV automation, to request a product brochure or download a free, educational white paper, visit www.baxa.com/ivroom/, call 800.567.2292 or email info@baxa.com.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging and administration of medications.  Key products used worldwide in hospitals and healthcare facilities include: the Abacus® Order Entry and Calculation Software, the DoseEdge® Pharmacy Workflow Manager, ExactaMed® Oral Syringes, ExactaMix® Automated Compounding Devices, InFuse™ and MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, NeoThrive® Enteral Syringes, the PadLock® Set Saver and the RapidFill™ and IntelliFill® i.v. Automated Syringe Fillers.  Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.  Further information is available at www.baxa.com.

Contact:
Marian Robinson, Vice President, Marketing
Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157
Email:  marian.robinson@baxa.com

Perrin McCormick
HB: 781-893-0053
Email: baxa@hbagency.com


'/>"/>
SOURCE Baxa Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):